OXiGENE Regains Nasdaq Closing Bid Price Compliance

OXiGENE Regains Nasdaq Closing Bid Price Compliance

(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, today announced that on January 14, 2013, Nasdaq
notified the Company that it regained compliance with the minimum $1.00 per
share closing bid price requirement for continued listing. As a result of
satisfying the minimum bid price requirement, this matter is now closed.

As previously announced, the Company received notice from Nasdaq on June 25,
2012 that the Company did not meet the minimum bid price rule required for
continued listing on The Nasdaq Capital Market. On December 26, 2012, Nasdaq
provided the Company until June 24, 2013 to achieve compliance with this


OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company's major focus is developing vascular
disrupting agents (VDAs) that selectively disrupt abnormal blood vessels
associated with solid tumor progression. OXiGENE is dedicated to leveraging
its intellectual property and therapeutic development expertise to bring
life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Any or all of the
forward-looking statements in this press release, including those pertaining
to OXiGENE's ongoing listing status with The Nasdaq Capital Market, may turn
out to be wrong. Forward-looking statements can be affected by inaccurate
assumptions OXiGENE might make or by known or unknown risks and uncertainties,
including, but not limited to, the Company's inability to obtain additional
financing or maintain its listing on the Nasdaq Capital Market. Additional
information concerning factors that could cause actual results to materially
differ from those in the forward-looking statements is contained in OXiGENE's
reports to the Securities and Exchange Commission, including OXiGENE's reports
on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to
publicly update forward-looking statements, whether because of new
information, future events or otherwise. Please refer to our Annual Report on
Form 10-K for the fiscal year ended December 31, 2011.

CONTACT: Investor and Media Contact:

company logo
Press spacebar to pause and continue. Press esc to stop.